Protein kinase C as a therapeutic target - PubMed (original) (raw)

Review

Protein kinase C as a therapeutic target

Beverly A Teicher. Clin Cancer Res. 2006.

No abstract available

PubMed Disclaimer

Similar articles

• A dose of reality for rational therapies.
  [No authors listed] [No authors listed] Nat Biotechnol. 2005 Mar;23(3):267. doi: 10.1038/nbt0305-267. Nat Biotechnol. 2005. PMID: 15765066 No abstract available.
• Selective antagonism of anticancer drugs for side-effect removal.
  Fernández A, Sessel S. Fernández A, et al. Trends Pharmacol Sci. 2009 Aug;30(8):403-10. doi: 10.1016/j.tips.2009.06.001. Trends Pharmacol Sci. 2009. PMID: 19595465
• Kinases as drug targets in the treatment of bipolar disorder.
  Catapano LA, Manji HK. Catapano LA, et al. Drug Discov Today. 2008 Apr;13(7-8):295-302. doi: 10.1016/j.drudis.2008.02.007. Epub 2008 Apr 3. Drug Discov Today. 2008. PMID: 18405841 Review.
• EGFR targeting therapies: monoclonal antibodies versus tyrosine kinase inhibitors. Similarities and differences.
  Dassonville O, Bozec A, Fischel JL, Milano G. Dassonville O, et al. Crit Rev Oncol Hematol. 2007 Apr;62(1):53-61. doi: 10.1016/j.critrevonc.2006.12.008. Epub 2007 Feb 26. Crit Rev Oncol Hematol. 2007. PMID: 17324578 Review.
• [Targeted therapy of dermatofibrosarcoma with imatinib].
  Ugurel S. Ugurel S. J Dtsch Dermatol Ges. 2007 Mar;5(3):261. doi: 10.1111/j.1610-0387.2007.07009.x. J Dtsch Dermatol Ges. 2007. PMID: 17338806 German. No abstract available.

Cited by

• Receptor tyrosine kinases regulate signal transduction through a liquid-liquid phase separated state.
  Lin CC, Suen KM, Jeffrey PA, Wieteska L, Lidster JA, Bao P, Curd AP, Stainthorp A, Seiler C, Koss H, Miska E, Ahmed Z, Evans SD, Molina-París C, Ladbury JE. Lin CC, et al. Mol Cell. 2022 Mar 17;82(6):1089-1106.e12. doi: 10.1016/j.molcel.2022.02.005. Epub 2022 Feb 28. Mol Cell. 2022. PMID: 35231400 Free PMC article.
• Molecular insight into isoform specific inhibition of PI3K-α and PKC-η with dietary agents through an ensemble pharmacophore and docking studies.
  Bhaskar BV, Rammohan A, Babu TM, Zheng GY, Chen W, Rajendra W, Zyryanov GV, Gu W. Bhaskar BV, et al. Sci Rep. 2021 Jun 9;11(1):12150. doi: 10.1038/s41598-021-90287-3. Sci Rep. 2021. PMID: 34108504 Free PMC article.
• Phosphorylation state of Ser165 in α-tubulin is a toggle switch that controls proliferating human breast tumors.
  Markovsky E, de Stanchina E, Itzkowitz A, Haimovitz-Friedman A, Rotenberg SA. Markovsky E, et al. Cell Signal. 2018 Dec;52:74-82. doi: 10.1016/j.cellsig.2018.08.021. Epub 2018 Sep 1. Cell Signal. 2018. PMID: 30176291 Free PMC article.
• IGF-1R and mTOR Blockade: Novel Resistance Mechanisms and Synergistic Drug Combinations for Ewing Sarcoma.
  Lamhamedi-Cherradi SE, Menegaz BA, Ramamoorthy V, Vishwamitra D, Wang Y, Maywald RL, Buford AS, Fokt I, Skora S, Wang J, Naing A, Lazar AJ, Rohren EM, Daw NC, Subbiah V, Benjamin RS, Ratan R, Priebe W, Mikos AG, Amin HM, Ludwig JA. Lamhamedi-Cherradi SE, et al. J Natl Cancer Inst. 2016 Aug 30;108(12):djw182. doi: 10.1093/jnci/djw182. Print 2016 Dec. J Natl Cancer Inst. 2016. PMID: 27576731 Free PMC article.
• The osteogenic or adipogenic lineage commitment of human mesenchymal stem cells is determined by protein kinase C delta.
  Lee S, Cho HY, Bui HT, Kang D. Lee S, et al. BMC Cell Biol. 2014 Nov 25;15:42. doi: 10.1186/s12860-014-0042-4. BMC Cell Biol. 2014. PMID: 25420887 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Silverchair Information Systems

• Other Literature Sources

  • The Lens - Patent Citations